

Human IgA Cross-Adsorbed Antibody

Goat Polyclonal Conjugate DyLight® 550

Antigen Affinity Purified

Catalog No. A80-202D3

Lot No. A80-202D3-10

APPLICATIONS	IHC, ICC, F, IF
SPECIES REACTIVITY	Human. Minimum reactivity to mouse and rat
AMOUNT	1 ml
CONCENTRATION	0.5 mg/ml
STORAGE/SHELF LIFE	2 – 8°C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Phosphate Buffered Saline (PBS) containing 0.2% BSA and 0.09% Sodium Azide
FLUOROPHORE/PROTEIN	5.5
ISOTYPE	IgG
ORIGIN	USA
PRODUCTION PROCEDURES	Antiserum was solid phase adsorbed to ensure class specificity. Antiserum was cross adsorbed using mouse and rat immunosorbents to remove cross reactive antibodies. The antibody to human IgA was isolated by affinity chromatography using antigen coupled to agarose beads and conjugated to DyLight® 550.

Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.

By immunoelectrophoresis and ELISA this antibody reacts specifically with human IgA. Cross reactivity with IgM and IgG is negligible. No antibody was detected against non-immunoglobulin serum proteins. Less than 1% cross reactivity to mouse and rat IgA was detected. This antibody may cross react with IgA from other species.

APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

- Immunohistochemistry 1:50 – 1:500
- Immunocytochemistry 1:50 – 1:500
- Flow Cytometry 1:50 – 1:200
- Immunofluorescence 1:50 – 1:500

APPLICATION NOTES Not all listed applications have been specifically tested by our laboratory.

DyLight® 550 is excited at 562 (in PBS) and emits at 576 (in PBS). DyLight® 550 replaces DyLight® 549.

DyLight® is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

ADDITIONAL INFO Please visit our website for additional product information.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Michael Spencer, PhD Date: July 19, 2022